Immuneering (NASDAQ:IMRX) Releases Earnings Results

Immuneering (NASDAQ:IMRX) released its quarterly earnings data on Thursday. The company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.16), Zacks reports.

Immuneering Price Performance

Shares of Immuneering stock opened at $1.80 on Friday. The stock has a market cap of $55.89 million, a P/E ratio of -0.91 and a beta of -0.32. The stock’s 50 day simple moving average is $1.79 and its 200-day simple moving average is $1.99. Immuneering has a 1-year low of $1.00 and a 1-year high of $3.83.

Analyst Upgrades and Downgrades

IMRX has been the subject of several recent analyst reports. Morgan Stanley lowered Immuneering from an “equal weight” rating to an “underweight” rating in a research note on Friday, December 13th. Needham & Company LLC restated a “buy” rating and issued a $12.00 price target on shares of Immuneering in a research note on Friday. Finally, Chardan Capital reiterated a “buy” rating and set a $13.00 price objective on shares of Immuneering in a research note on Wednesday, January 8th.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.